REGEN BIOPHARMA, INC.: MESSAGE TO THE SHAREHOLDERS FROM THE CHAIRMAN AND CHIEF EXECUTIVE OFFICER

Rhea-AI Summary

Regen BioPharma (PINK: RGBP, RGBPP) has made significant strides under CEO David R. Koos since March 2021, overcoming financial and legal challenges. The company revived valuable intellectual property, settled a $1.2M lawsuit, and became current with SEC filings, safeguarding its public trading status. In Q3 2021, Regen generated $1.9M from licensing agreements, although revenue accounting will be adjusted per ASC 606. Looking ahead, Koos aims to secure more collaborations to advance clinical trials without drawing a salary, reflecting his commitment to the company’s future.

Positive

• Revived valuable existing IP previously deemed abandoned by the USPTO.
• Settled a lawsuit with Chemdiv, mitigating $1.2M in potential damages.
• Issued several new patents and entered two licensing agreements.
• Became current in SEC filing obligations, ensuring trading status.
• Generated $1.9M in Q3 2021 from two licensing agreements.

Negative

• Revenue recognition adjustment needed for compliance with ASC 606, possibly impacting financial perception.

 

SAN DIEGO, Dec. 30, 2021 /PRNewswire/ -- Regen BioPharma, Inc. (PINK: RGBP) and (PINK: RGBPP):

First of all I would like to wish all our shareholders a happy holiday season.  It has been a long year with many challenges and many successes.

When I returned to Regen on March 23, 2021 in order to serve as Chairman and Chief Executive Officer I found myself at the helm of a company on the verge of collapse. We were behind in bills, at risk of losing patent protection on valuable IP, and delinquent in our SEC filing obligations. Worse of all we were being sued by  Chemdiv-our Contract Research Organization- in a complaint seeking damages of $1,200,000 which also threatened our ownership rights to valuable intellectual property

As the year progressed we faced the challenges that lay before us and conquered them. Regen has revived numerous valuable existing IP which had been deemed abandoned by the United States Patent and Trademark Office, settled its lawsuit with Chemdiv, been issued several new patents, entered into two non-related party licensing agreements and became current in its SEC filing obligations eliminating the risk that the public trading market for both the common and Series A preferred shares would disappear.

Becoming current in our SEC reporting obligations after such a long delinquency was a significant achievement.  Recent amendments to SEC Rule 15c2-11 threatened the public trading status of delinquent issuers.  Had I not been able to get the Company current there was a real possibility that   our shareholders wouldn't be able to trade their shares and the Company's ability to raise capital would be adversely effected.

I have received numerous texts, emails and phone calls regarding our restatement of our third quarter financials.

During the quarter ended June 30, 2021 the Company was paid $1,905,000 in cash and securities resulting from two licenses granted in April, 2021 to Oncology Pharma, Inc. ("ONPH").

Pursuant to the terms and conditions of the licenses granted   ONPH became obligated to:
(a) Pay nonrefundable fees of $55,000 and fifty thousand common shares of ONPH no later than April 20, 2021

(b) Pay royalties equal to five percent (5%) of the Net Sales (as Net Sales are defined in the Agreement) of any Licensed Products in a quarter.

Accounting for Revenues from contracts with customers and licensees is governed by Accounting Standard Codification 606 ("ASC 606") issued by the Financial Accounting Standards Board ("FASB").

ASC 606 requires that revenue be recognized as performance obligations are fulfilled. In considering the accounting for revenue generated by the licenses, the Company initially determined that the nonrefundable fees paid were consideration solely for entering into the agreement   and thus should be recognized within the quarter in which they were paid.

A subsequent examination in conjunction with the Company's public accountant led us to reconsider this accounting treatment and we determined that – in order to be compliant with ASC 606- the revenue generated by the payment to the Company of the nonrefundable fees would need to be recognized over the term of the licenses. We arrived at the conclusion that entering into the agreement did not adequately meet the criteria of being "distinct within the context of the contract" from the obligation of granting the license over the term of the contract. None of the abovementioned changes the fact that $1,905,000 in cash and securities was paid to the Company during the quarter ended June 30, 2021 and this payment was nonrefundable.

Looking into the New Year I will work diligently towards the goal of entering into additional co-development projects and collaborations that I believe will benefit Regen's shareholders and   I expect to identify a contract research organization that will help us move the Company's intellectual propriety towards clinical trials. 

During this past year I haven't taken a dime in salary from Regen. The reason for this is because I see our company for all its potential and possibilities and I'm betting on what we have and what we can achieve.

Sincerely,
David R. Koos
Chairman & CEO
Regen BioPharma Inc.

About Regen BioPharma Inc.: 
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax
david.koos@regenbiopharma.com
http://www.regenbiopharmainc.com

View original content:https://www.prnewswire.com/news-releases/regen-biopharma-inc-message-to-the-shareholders-from-the-chairman-and-chief-executive-officer-301452028.html

SOURCE Regen BioPharma, Inc.

FAQ

What milestones has Regen BioPharma achieved in 2021?

Regen BioPharma revived valuable IP, settled a $1.2M lawsuit, and became current with SEC filings.

How much revenue did Regen BioPharma generate in Q3 2021?

Regen BioPharma generated $1.9M in cash and securities from licensing agreements.

What is the significance of Regen BioPharma's SEC filing status?

Being current with SEC filings protects the public trading status for RGBP and RGBPP shares.

Who is leading Regen BioPharma?

David R. Koos serves as Chairman and CEO of Regen BioPharma.

What future goals does Regen BioPharma have?

Regen BioPharma aims to enter into additional collaborations and move its intellectual property toward clinical trials.